Niraparib

About

Therapy type: Targeted therapy

Therapy strategy: PARP inhibition

Mappings

NCI Thesaurus: Niraparib (coding:ncit:C80059)

RxNorm: niraparib (coding:rxcui:1918231, coding:omop:1593861)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (2) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
EMA (1) FDA (2) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
EMA (1) FDA (4) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
EMA (1) FDA (4) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (2) BRCA1 pathogenic variants Ovarian Epithelial Tumor Niraparib
FDA (2) BRCA2 pathogenic variants Ovarian Epithelial Tumor Niraparib
FDA (2) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
FDA (2) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
FDA (2) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Niraparib
FDA (2) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Niraparib
EMA (2) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
EMA (2) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
EMA (2) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
EMA (2) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone